Scans of neck blood vessels after head and neck cancer radiation
Tests sodium fluoride F-18 scans in head and neck cancer.
Key facts
- Who runs it
- Emory University
- Where
- Atlanta, United StatesSee the site
- Trial code
- Registry title
- PET/CT Assessment of Radiation-Induced Vascular Complications in Head and Neck Cancer
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 20 people, planned
- Started
- 3 Dec 2024
- Expected to end
- 31 Aug 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Computed Tomography
- Fludeoxyglucose F-18
- Intensity-Modulated Proton Therapy
- Intensity-Modulated Radiation Therapy
- Positron Emission Tomography
- Sodium Fluoride F-18
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with head and neck cancer who will have chemoradiotherapy without surgery. It compares an F-18 NaF PET/CT scan with the standard scan to see how radiation affects neck blood vessels.
- Age
- 18 years and older
- Sex
- Men and women
- Disease stage
- Squamous cell carcinoma of the oropharynx (HPV-negative), larynx or hypopharynx, clinical stage III-IVb. Or HPV-associated squamous cell carcinoma of the oropharynx, clinical stage I-III. Treatment is meant to remove all of the disease without surgery.
- Earlier treatment
- Must be treated with chemotherapy given together with radiation as standard care. Cannot have had chemotherapy or radiotherapy within 4 weeks before joining.
- Biomarker or test result
- Oropharynx cancer may be HPV-negative or HPV-associated, depending on the stage.
Main reasons for not taking part
- Pregnant women
- Adults who cannot give consent, and prisoners
- Other investigational drug or device within 21 days before the first F-18 NaF scan
- Planned immunotherapy during or after radiation, before the second scan
- Serious heart or blood vessel disease, or uncontrolled illness
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Males and females 18 years of age and older
- Diagnosis of clinical stage III-IVb (American Joint Committee on Cancer [AJCC] 8th edition) squamous cell carcinoma of the oropharynx (human papillomavirus [HPV]-negative), larynx, or hypopharynx, or clinical stage I-III (AJCC 8th edition) HPV-associated squamous cell carcinoma of the oropharynx receiving curative-intent, organ preservation (non-surgical)
- Treatment with concurrent chemoradiotherapy per institutional standard of care at the discretion of Medical Oncology. RT is delivered per institutional standard of care at the discretion of Radiation Oncology
- Patients must give protocol-specific consent on an Institutional Review Board (IRB)-approved consent form prior to completion of protocol-specific testing/procedures
- Women are eligible to participate in the study if they meet one of the following criteria:; Females of childbearing potential (FCBP) must have a negative pregnancy test at baseline and follow-up visit. Women of childbearing potential must undergo pregnancy testing during each study visit and agree to use at least one of the following methods of contraception throughout the study duration:; Oral contraceptives, transdermal contraceptives, injectable or implantable methods, intrauterine devices, and/or vaginal ring; Women who are postmenopausal (for at least one year), sterile, or hysterectomized; Women who have undergone tubal ligation will be required to undergo pregnancy testing during each study visit
Who cannot take part
- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier (i.e., have residual toxicities > grade 1)
- Patients who are receiving any other investigational agents or an investigational device within 21 days before administration of the F-18 NaF for the pre-RT PET/CT imaging
- Patients planned to receive any immunotherapy agent during their radiotherapy or in the interval between radiotherapy and post-RT PET/CT imaging
- Significant cardiovascular disease (eg, myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 3 months prior to study entry; angina requiring therapy; symptomatic peripheral vascular disease; New York Heart Association class 3 or 4 congestive heart failure; or uncontrolled grade >= 3 hypertension (diastolic blood pressure >= 100 mmHg or systolic blood pressure >= 160 mmHg) despite antihypertensive therapy
- History of allergic reactions attributed to compounds of similar chemical or biological composition to F-18 NaF or other agents used in the study
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Adults who are unable to consent
- Pregnant women
- Prisoners
Where in United States
- Emory University Hospital MidtownAtlanta, United StatesContact: Nashwa M. JarkasTaking people
About the trial
What the trial wants to find out
This early phase I trial compares sodium fluoride F-18 (F-18 NaF) positron emission tomography (PET)/computed tomography (CT) to the standard of care imaging scan (and fludeoxyglucose F-18 [F-18 FDG] PET/CT) for assessing the effects radiation therapy has on the blood vessels in the neck in patients with head and neck cancers. For people with cancers in the head and neck, doctors often use radiation to target both the tumor and nearby glands. Radiation therapy to this region can affect the blood vessels in the neck that supply blood to the brain. F-18 NaF and F-18 FDG are contrast agents that can be used together with PET/CT imaging to visualize areas inside the body. A PET scan is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. A CT scan is a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body. The pictures are taken from different angles and are used to create 3-dimensional views of tissues and organs. Combining a PET scan with a CT scan can help make the image easier to interpret. PET/CT scans are hybrid scanners that combine both modalities into a single scan during the same examination. Imaging with F-18 NaF PET/CT may be as effective or more effective than the standard F-18 FDG PET/CT for assessing the effects radiation therapy has on blood vessels in the neck in patients with head and neck cancers.
The 2 groups in the trial
- Arm I (F-18 NaF PET/CT)Treatment being tested
Patients receive F-18 NaF IV and undergo PET/CT within 28 days of each SOC F-18 FDG PET/CT on study, once prior to initiation of SOC IMRT and once 12 weeks after completion of SOC IMRT.
Treatment: Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Positron Emission Tomography, and Sodium Fluoride F-18
- Arm II (F-18 NaF PET/CT)Treatment being tested
Patients receive F-18 NaF IV and undergo PET/CT within 28 days of each SOC F-18 FDG PET/CT on study, once prior to initiation of SOC IMPT and once 12 weeks after completion of SOC IMPT.
Treatment: Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy, Positron Emission Tomography, and Sodium Fluoride F-18
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessment of Radiation-Induced Vascular Complications in Patients With Head and Neck Cancers With PET/CT Imaging
- Plain-language title
- Scans of neck blood vessels after head and neck cancer radiationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 November 2026